Using Regression Discontinuity in Time to Strengthen Real-World Evidence: A Case Study in Lung Cancer.

Nai-Chia Chen¹, Antal T Zemplenyi¹, Blythe Adamson², Alex M Kaizer³, Cindy L O'Bryant¹, R Brett McQueen¹, Kelly E Anderson^1,4

¹Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA.

²Flatiron Health, Inc., New York, NY, USA.

³Department of Biostatistics and Informatics, University of Colorado School of Public Health, Aurora, CO, USA.

⁴Harvard Medical School and Brigham and Women's Hospital, Harvard University, Cambridge, MA, USA.

PubMed DOI

Abstract

ObjectiveReal-world evidence is increasingly leveraged to assess treatment effectiveness outside of clinical trials, yet unmeasured confounders and missing data pose challenges to causal inference, which is particularly problematic when incorporating historical controls that lack recent prognostic factors. We applied the regression discontinuity in time (RDiT) design, a quasi-experimental approach…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.